Patent application number | Description | Published |
20090214101 | Targeted Nanostructures for Cellular Imaging - Compositions and methods related to targeted carbon nanostructures. More particularly, targeted carbon nanostructures comprising: a C | 08-27-2009 |
20100068151 | MULTIMODALITY MOLECULAR IMAGING WITH THERAPEUTIC CONJUGATES - Disclosed are pharmaceutical compounds comprising a cell-specific targeting moiety, an anti-cell proliferation moiety, and a chelator moiety. Also disclosed are methods for treating a subject with a hyperproliferative disease, methods for diagnosing presence of a hyperproliferative disease in a subject, and methods for detecting a therapeutic response in a subject that employ the pharmaceutical compounds of the present invention. | 03-18-2010 |
20110002910 | THERAPEUTIC AGENTS COMPRISING PRO-APOPTOTIC PROTEINS - The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax. | 01-06-2011 |
20110288275 | Modified Proteins, Designer Toxins, and Methods of Making Thereof - The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositions have significant benefits to a subject in need of such compounds and compositions. Also included are modified toxin compounds that are truncated and/or possess reduce antigenicity. Such designer toxins have therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins. Methods of treating cancer using these immunotoxins are provided. | 11-24-2011 |
20120252097 | Therapeutic Agents Comprising Pro-Apoptotic Proteins - The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax. | 10-04-2012 |
20140140976 | SERINE PROTEASE MOLECULES AND THERAPIES - Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided. | 05-22-2014 |
20140314760 | SERINE PROTEASE MOLECULES AND THERAPIES - Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided. | 10-23-2014 |
20150368628 | DEIMMUNIZED GELONIN MOLECULES AND THERAPIES - Recombinant gelonin polypeptides with decreased antigenicity are provided. Cell-targeted constructs comprising said recombinant gelonin polypeptides are also provided. Such constructs can be used in methods for targeted cell killing, such as for treatment of cell proliferative diseases (e.g., cancer). | 12-24-2015 |